Acknowledgements
Cancer, TMP-IL, Anderson Cancer, A., Lung Cancer
CANCER, LUNG, THORACIC, ONCOLOGY, LUNG CANCER
Funding support for the clinical trial was provided by Bristol Myers Squibb. Support for the study was also partially provided by the National Institutes of Health (NIH)/National Cancer Institute (NCI) through The University of Texas Lung Specialized Program of Research Excellence SPORE grant 5P50CA070907 (to T.C., L.A.B., F.S., I.I.W., D.L.G. and J.V.H.); the NIH/NCI P30 CA016672 Cancer Center Support Grant (to the Microbiome Core Facility, the Advanced Technology Genomic Core, the Flow Cytometry and Cellular Imaging Core Facility, the Bioinformatics Shared Resource and the Biostatistics Resource Group); NIH 1S10OD024977-01 (to the Advanced Technology Genomic Core); NCI T32CA217789, MD Anderson Cancer Center postdoctoral fellowship (to A.S.); NIH/NCI R01CA248731 (to H.K.); NIH/NCI R01CA262425 (to T.C. and J. Wu); and the Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018 (to T.C.). H.K. is an Andrew Sabin Family Foundation Fellow of The University of Texas MD Anderson Cancer Center. The study was also partially supported by generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program (to T.C., J. Wu, D.L.G., B.S. and J.V.H.); the Physician Scientist Program (to T.C.); the Khalifa Scholar Award from the Khalifa Bin Zayed Al Nahyan Foundation (to T.C.); the Rexanna’s Foundation for Fighting Lung Cancer (to T.C.); and the Bob Mayberry Foundation (to T.C.). We thank the patients and their families for participating in this study. We thank all members of our regulatory, clinical, data coordination and translational research teams in the Departments of Thoracic/Head and Neck Medical Oncology and Thoracic Surgery at MD Anderson Cancer Center for their support on this trial. We thank members of the strategic alliance teams at Bristol Myers Squibb and MD Anderson Cancer Center for their support. We thank members of the Translational Molecular Pathology Immune-Profiling Laboratory (TMP-IL); B. Sanchez Espiridon and S. Wijeratne for their assistance with sample procurement and inventory; and M. Jiang for technical assistance. We thank the MD Anderson Program for Innovative Microbiome and Translational Research (PRIME-TR) for supporting the analysis and interpretation of the microbiome results presented here (J.A.W. and N.J.A. are the program director and executive scientific director for PRIME-TR, respectively). We thank A. Khan (program director) and M. Polk (administrative director) for logistic support and other members of the Immunotherapy Platform at MD Anderson Cancer Center for technical support and scientific input (J.P.A. and P.S. are the executive director and scientific director of the Immunotherapy Platform, respectively). We thank R. Jenq and T. Chang, co-director and manager of the Microbiome Core Facility at MD Anderson Cancer Center, respectively, for their support and guidance with gut microbiome sequencing.